Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone 250 mg Without ADT in Prostate Cancer
NCT07299292Phase 2Recruiting
- Sponsor
- SMED Clinical Research
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of abiraterone in prostate cancer (PCa), sponsored by SMED Clinical Research. Primary endpoints: Proportion of patients with serum testosterone <=50 ng/dL at 30 days and Time to castration at 30 days. Started Dec 2025; status: recruiting.
02
Drugs
abiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07299292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07299292.